Literature DB >> 26131231

Dipeptidyl peptidase 4 concentration influenced by serum insulin levels rather than arterial stiffness index in type 2 diabetics.

Liming Wu1, Qing Gong2, Risu Na1, Xudong Mao1, Xulei Zheng1, Qiaorui Liu1, Cong Ma1, Xin Ding1, Hongguang Sheng1, Zhiwen Liu1.   

Abstract

OBJECTIVE: To investigate whether inhibitors of dipeptidyl peptidase-4 (DPP-4) can suppress the atherosclerotic development in diabetic patients.
METHODS: The prospective study was carried out in the Out-patient Department of XuHui Central Hospital, Shanghai, China, between March and August 2013. The correlation of major index of glucose and lipid metabolism profiles, and the arterial stiffness index (AI) between diabetic patients and healthy subjects were analyzed. PATIENTS OR MATERIALS: 39 patients with type 2 diabetes and 29 healthy subjects were enrolled for measurements of blood glucose, plasma insulin, HbA1c, TC, cholesterol, HDL, AI and body mass index (BMI).
RESULTS: Significant differences were found between DPP-4 and blood glucose (fasting and 2 h postprandial), HbA1c, cholesterol, high density lipoprotein and arterial stiffness in normal subjects and diabetic patients. Only the fasting insulin concentration and high density lipoprotein had a significant impact on DPP-4 levels.
CONCLUSIONS: It was clear that insulin (fasting) and HDL levels had an impact on DPP-4 activity but only in patients with Type 2 diabetes. The arterial stiffness index was not correlated with DPP-4 levels in Type 2 diabetic patients.

Entities:  

Keywords:  Arterial stiffness index; DPP-4; HDL; cholesterol; insulin

Year:  2015        PMID: 26131231      PMCID: PMC4483849     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  10 in total

1.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

2.  Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.

Authors:  M B Toft-Nielsen; S Madsbad; J J Holst
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

3.  DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.

Authors:  Nga N Ta; Yanchun Li; Corinne A Schuyler; Maria F Lopes-Virella; Yan Huang
Journal:  Atherosclerosis       Date:  2010-08-26       Impact factor: 5.162

4.  Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.

Authors:  M Barbieri; M R Rizzo; R Marfella; V Boccardi; A Esposito; A Pansini; G Paolisso
Journal:  Atherosclerosis       Date:  2013-01-17       Impact factor: 5.162

5.  Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).

Authors:  Naoto Katakami; Tomoya Mita; Hidenori Yoshii; Tomio Onuma; Hideaki Kaneto; Takeshi Osonoi; Toshihiko Shiraiwa; Keisuke Kosugi; Yutaka Umayahara; Tsunehiko Yamamoto; Hiroki Yokoyama; Nobuichi Kuribayashi; Hideaki Jinnouchi; Masahiko Gosho; Hirotaka Watada; Iichiro Shimomura
Journal:  J Atheroscler Thromb       Date:  2013-08-20       Impact factor: 4.928

6.  Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.

Authors:  J Dupre; M T Behme; I M Hramiak; P McFarlane; M P Williamson; P Zabel; T J McDonald
Journal:  Diabetes       Date:  1995-06       Impact factor: 9.461

Review 7.  DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.

Authors:  Dror Dicker
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

8.  Glucagon-like peptide 1 improved glycemic control in type 1 diabetes.

Authors:  Margaret T Behme; John Dupré; Thomas J McDonald
Journal:  BMC Endocr Disord       Date:  2003-04-10       Impact factor: 2.763

9.  Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.

Authors:  Michishige Terasaki; Masaharu Nagashima; Kyoko Nohtomi; Kyoko Kohashi; Masako Tomoyasu; Kyoko Sinmura; Yukinori Nogi; Yuki Katayama; Kengo Sato; Fumiko Itoh; Takuya Watanabe; Tsutomu Hirano
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

10.  The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.

Authors:  Yanmei Zeng; Chenzhong Li; Meiping Guan; Zongji Zheng; Jingjing Li; Wenwei Xu; Ling Wang; Feiying He; Yaoming Xue
Journal:  Cardiovasc Diabetol       Date:  2014-02-04       Impact factor: 9.951

  10 in total
  1 in total

1.  High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case-control study.

Authors:  Shajith Anoop; Anoop Misra; Surya Prakash Bhatt; Seema Gulati; Ravindra Mohan Pandey; Harsh Mahajan
Journal:  BMJ Open Diabetes Res Care       Date:  2017-11-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.